Salarius Pharmaceuticals, Inc.
SLRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $1 | $2 |
| - Cash | $5 | $1 | $2 | $2 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$3 | $1 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$1 | -$1 | -$2 | -$1 |
| % Margin | – | – | – | – |
| Net Income | -$1 | -$1 | -$2 | -$1 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.81 | -6.75 | -15.45 | -22.8 |
| % Growth | 73.2% | 56.3% | 32.2% | – |
| Operating Cash Flow | -$2 | -$1 | -$1 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2 | -$1 | -$1 | -$1 |